Simvastatin
| Evidence Level: L1 | Predicted Indications: 8 |
Table of Contents
- Simvastatin
- Simvastatin: From Hyperlipidemia and Atherosclerotic Disease to Familial Hypercholesterolemia
Simvastatin: From Hyperlipidemia and Atherosclerotic Disease to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is a statin (HMG-CoA reductase inhibitor) originally used for hyperlipidemia, hypertriglyceridemia, atherosclerosis and stroke-related conditions. The TxGNN model predicts it may be effective for familial hypercholesterolemia, with 8 clinical trials and 19 publications currently supporting this direction. The prediction largely overlaps with the drug’s existing uses (homozygous familial hypercholesterolemia is already among its listed indications), so it is closer to on-label use than true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyperlipidemia, hypertriglyceridemia, atherosclerosis, stroke and cerebral infarction (from the knowledge graph; no approved-indication text is available from the US licence records) |
| Predicted New Indication | Familial hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| US Market Status | Cancelled only (all 6 listed licences are cancelled) |
| Number of NDAs | 6 (all ANDAs; none currently valid) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Simvastatin inhibits HMG-CoA reductase, which lowers hepatic cholesterol synthesis and upregulates LDL receptors. This increases LDL-C clearance from the blood. Detailed mechanism-of-action data were not available in the data compiled for this report, but this is the well-established pharmacology of the statin class.
Familial hypercholesterolemia is a genetic disorder of LDL-C clearance, and statins act on the same pathway. The disease is already close to simvastatin’s existing indications (homozygous familial hypercholesterolemia and hyperlipoproteinemia). The prediction is therefore mechanistically sound but is not a novel repurposing opportunity.
Clinical Trial Evidence
Most trials below test simvastatin as part of a combination or as background therapy, so they do not all show its stand-alone effect.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE: ezetimibe plus high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT00129402 | Phase 3 | Completed | 248 | Ezetimibe co-administered with simvastatin in adolescents (10-17 years) with heterozygous FH |
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe 10 mg added to atorvastatin or simvastatin in homozygous FH |
| NCT03885921 | Phase 3 | Completed | 44 | Long-term (up to 24 months) safety of ezetimibe added to atorvastatin or simvastatin in homozygous FH |
| NCT01709500 | Phase 3 | Completed | 249 | Alirocumab vs placebo in heterozygous FH on lipid-modifying therapy; simvastatin’s role unclear (possible background therapy) |
| NCT03510884 | Phase 3 | Completed | 153 | Alirocumab in children and adolescents with heterozygous FH on stable statin therapy; simvastatin is likely background |
| NCT00654446 | Phase 3 | Completed | 442 | Renal effects of rosuvastatin and simvastatin over 6 weeks in type IIa/IIb dyslipidaemia, including heterozygous FH |
| NCT03510715 | Phase 3 | Completed | 18 | Open-label alirocumab in children with homozygous FH; simvastatin at most background (low relevance) |
| NCT01890967 | Phase 2 | Completed | 527 | LY3015014 dose-ranging in primary hypercholesterolemia on statins; indirect relevance |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18376000 | 2008 | Clinical trial (ENHANCE) | N Engl J Med | Simvastatin with or without ezetimibe in familial hypercholesterolemia, with carotid atherosclerosis progression as the endpoint |
| 12034651 | 2002 | Randomized trial | Circulation | Ezetimibe added to atorvastatin or simvastatin in 50 patients with homozygous FH |
| 11383320 | 2001 | RCT | Nutr Metab Cardiovasc Dis | Atorvastatin vs simvastatin for LDL-C goal attainment in heterozygous FH |
| 31696945 | 2019 | Cochrane systematic review | Cochrane Database Syst Rev | Statins for children with familial hypercholesterolemia |
| 12908847 | 2003 | Review | Drug Saf | Benefits and risks of simvastatin in familial hypercholesterolaemia |
| 15794711 | 2005 | Review | Expert Opin Drug Saf | Long-term safety and tolerability of simvastatin in FH |
| 2679083 | 1989 | Clinical study | Am J Med | Simvastatin 20 mg then 40 mg lowered LDL-C by about 38% and 42% in FH |
| 35629051 | 2022 | Cross-sectional study | J Clin Med | Cellular immunity parameters in 26 children with FH, 13 on simvastatin 10 mg |
| 41824590 | 2026 | Guideline | J Am Coll Cardiol | 2026 ACC/AHA multi-society dyslipidemia guideline, replacing the 2018 cholesterol guideline |
| 28437620 | 2017 | Guideline | Endocr Pract | AACE/ACE guidelines for dyslipidemia management and cardiovascular prevention |
US Market Information
All six US licences are cancelled; none are currently valid. Approved-indication text was not available.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA077691 | Simvastatin (A-S Medication Solutions) | Film-coated tablet | Not available |
| ANDA078103 | Simvastatin (St. Mary’s Medical Park Pharmacy) | Film-coated tablet | Not available |
| ANDA078155 | Simvastatin (Accord Healthcare) | Film-coated tablet | Not available |
| ANDA200895 | Simvastatin (Quallent Pharmaceuticals Health) | Film-coated tablet | Not available |
| ANDA078034 | Simvastatin (RemedyRepack) | Film-coated tablet | Not available |
Safety Considerations
- Contraindications and disease associations (knowledge graph, not label text): The knowledge graph flags a number of conditions, including liver disease, pancreatitis, gallbladder disease, myopathy and other muscle diseases, rhabdomyolysis, diabetes and hyperglycemia, diabetic ketoacidosis, gout, thrombocytopenia, blood coagulation disease, peptic ulcer disease, hypotensive disorder, substance abuse/dependence, and several coronary conditions (acute coronary syndrome, coronary artery disease, myocardial infarction). These need verification against the current package insert.
- Drug Interactions: 100 interactions were recorded. Major-level ones include amiodarone, amlodipine and fenofibrate. Moderate-level ones include nifedipine, omeprazole, paclitaxel, aprepitant, alpelisib, apalutamide, zidovudine and ethanol. Strong CYP3A4 inhibitors, such as ritonavir- or cobicistat-boosted HIV regimens, are of particular concern for myopathy and rhabdomyolysis.
- Dose-related risk: The 80 mg dose carries a higher myopathy risk. Pediatric dosing and heterozygous versus homozygous disease also need attention.
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for the full safety information.
Other Predicted Indications (Brief)
| Predicted Indication | Score | Evidence | Decision |
|---|---|---|---|
| Hypercholesterolemia, autosomal dominant | 99.36% | L1 (overlaps with familial hypercholesterolemia) | Proceed with Guardrails |
| HIV infectious disease | 99.22% | L3 (Phase 1 DDI studies only; simvastatin has no antiviral effect and strong CYP3A4 inhibitors restrict its use) | Research Question |
| Brain stem infarction | 99.41% | L5 (no trials; a subtype of an existing use) | Hold |
| CETP deficiency, CYP7A1-deficiency hypercholesterolemia, ABri amyloidosis, a rare neurodevelopmental disorder | 99.38% to 99.10% | L5 (prediction only, no studies) | Hold |
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 trials and a large body of literature support simvastatin in familial hypercholesterolemia, and the mechanism is well understood. However, this is largely an existing use rather than new repurposing, and the supporting trials mostly test simvastatin in combination or as background therapy. Safety information from the package insert is missing.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism-of-action data from DrugBank
- Confirmation that a valid US licence exists, since all six listed licences are cancelled
- Guardrails for heterozygous vs homozygous disease, pediatric dosing, high-dose myopathy risk, and CYP3A4 interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.